EcoDrugPlus

Dopamine Receptor D4

Ensembl ID : ENSUPAG00010022884
Gene Symbol: DRD4
3 Cross references
246 Possible Orthologues:

Dopamine Receptor D5

Ensembl ID : ENSUPAG00010016614
Gene Symbol: DRD5
3 Cross references
186 Possible Orthologues:

Ectonucleotide Pyrophosphatase/phosphodiesterase 2

Ensembl ID : ENSUPAG00010018003
Gene Symbol: ENPP2
3 Cross references
227 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSUPAG00010021616
Gene Symbol: EGLN1
1 Cross references
229 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 2

Ensembl ID : ENSUPAG00010022428
Gene Symbol: EGLN2
1 Cross references
190 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSUPAG00010001862
Gene Symbol: EGLN3
1 Cross references
206 Possible Orthologues:

Elastase, Neutrophil Expressed

Ensembl ID : ENSUPAG00010014669
Gene Symbol: ELANE
3 Cross references
102 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSUPAG00010020676
Gene Symbol: EPAS1
1 Cross references
222 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSUPAG00010000137
Gene Symbol: EDNRA
1 Cross references
265 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSUPAG00010014474
Gene Symbol: EDNRB
1 Cross references
264 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSUPAG00010020450
Gene Symbol: EZH2
3 Cross references
222 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSUPAG00010011920
Gene Symbol: EGFR
1 Cross references
285 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).